GET DAILY SIGNALSMyomo (MYO) Reports +22% Revenue Growth in Q3 2026 and Reaches Adjusted EBITDA Break-Even
Key Takeaways
- Myomo reported third-quarter 2026 revenue of $12.33 million, up about 22% from $10.09 million a year earlier and above the consensus estimate of roughly $11.5 million.
- Gross margin expanded to 71.3%, up from 63.8% in the prior-year quarter, helped by a higher average selling price and lower material costs.
- The company reached adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) break-even, compared with a loss of $2.7 million a year ago.
- Net loss was $4.2 million, or $0.10 per share, which included a non-cash charge of about $1.8 million tied to the valuation of derivative liabilities.
- Management narrowed its full-year 2026 revenue guidance to $46 million to $47 million, at the upper end of its prior $45 million to $47 million range.
Earnings Context and Why It Matters
Myomo, a wearable medical robotics company, develops and markets the MyoPro product line, a powered upper-limb orthosis that uses the patient's own EMG signals to restore arm and hand function for people with neurological disorders and upper-limb paralysis. The third-quarter report matters because it tests whether the company's push toward scale and operating leverage is translating into a clear path to profitability. Investors have been watching revenue growth, gross margin, cash burn, and the MyoConnect referral program, all of which signal how efficiently MYO is converting demand into revenue while controlling costs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Myomo posted revenue of $12.33 million, a year-over-year increase of roughly 22% and above the consensus estimate of about $11.5 million. Gross margin rose to 71.3% from 63.8% in the prior-year quarter, driven by a higher average selling price, lower material costs, and fixed-cost leverage on higher revenue units.
The company reached adjusted EBITDA break-even, compared with a loss of $2.7 million in the same period last year. Operating loss narrowed to $1.7 million from $3.5 million. Net loss was $4.2 million, or $0.10 per share, versus $3.7 million, or $0.09 per share, a year earlier; the quarter included a non-cash charge of approximately $1.8 million related to a market adjustment on derivative liabilities, as well as interest expense associated with the Avenue Capital term loan.
Market Reaction and Investor Sentiment
The market responded positively to the report, with MYO shares moving higher in the session following the announcement. Investors appeared to focus on the revenue beat, the sharp gross-margin expansion, and the achievement of adjusted EBITDA break-even, rather than the headline net loss per share, which was pressured by non-cash derivative-related charges. The narrowed full-year guidance, now at the top of the prior range, reinforced confidence that the company's operating leverage story remains intact heading into the fourth quarter.
Forward Outlook and Key Factors to Monitor
Management narrowed its full-year 2026 revenue guidance to $46 million to $47 million, signaling confidence in the remainder of the year. The company also expects a modest sequential increase in gross margin in the fourth quarter, reflecting the benefit of manufacturing cost-reduction initiatives.
Investors should watch operating expenses, which management expects to rise modestly in the fourth quarter due to one-time costs tied to a leadership transition and higher headcount supporting the MyoConnect program. Myomo reiterated its objective of limiting full-year operating-expense growth to half the rate of revenue growth.
Cash management remains a key theme. The company expects total cash burn in the second half of 2026 to stay below $2 million, including less than $500,000 in the fourth quarter. Other factors to monitor include pipeline growth, referral conversion, and whether the efficiency improvements in direct-to-patient lead generation continue to support order volume into 2027.
Using AI Tools in My Research Process
When reviewing earnings like those from MYO, I often rely on Tickeron’s AI Screener to quickly surface comparable names and test assumptions around margins and growth. It allows me to filter by industry, fundamentals, and recent performance in a structured way, which helps confirm whether the operating leverage story here stands out relative to peers. This kind of tool keeps the analysis efficient without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MYO in upward trend: price rose above 50-day moving average on November 09, 2026
MYO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MYO's RSI Indicator exited the oversold zone, 33 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where MYO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MYO as a result. In 58 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for MYO just turned positive on November 03, 2026. Looking at past instances where MYO's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
Following a +17.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYO advanced for three days, in 196 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The 10-day moving average for MYO crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
MYO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MYO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.221) is normal, around the industry mean (4.142). P/E Ratio (-3.559) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.262) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. MYO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of neuro-robotic technology
Industry MedicalNursingServices
Advertisement